Has Corey Ponder, MD received payments from drug or device companies?

Yes. Drug and device makers reported $291,296 in general payments to Corey Ponder, MD across 398 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Corey Ponder, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Corey Ponder, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Corey Ponder, MD

Adult Reconstructive Orthopaedic Surgery · Oklahoma City, OKNPI 1982743787

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $200,937 of the $291,296 with a category attached, or 69.0%. 15 manufacturers reported payments, led by Omnilife Science, Inc at 47.8% of the total. Reporting peaked in 2019 at $115,776 and has fallen 79.1% since, to $24,161 in 2025.

$291,296in general payments, 2019–2025

Across 398 payments — averaging $731.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Omnilife Science, Inc$139K
Stryker$107K
Medacta USA, Inc.$32K
Naviswiss, Inc.$11K
Corin USA$1K
Nalu Medical, Inc.$230
plus $405 from 9 others

$28,915in research payments, 2019–2025

Across 18 payments — averaging $1606.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Omnilife Science, Inc$29K

What the payments were for

Royalty or licence$3,7521%
Consulting fees$200,93769%
Travel & lodging$72,64525%
Food & beverage$13,9625%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Omnilife Science, Inc	152	$139,213
Stryker	133	$106,859
Medacta USA, Inc.	79	$32,483
Naviswiss, Inc.	15	$10,868
Corin USA	6	$1,237
Nalu Medical, Inc.	2	$230
Aesculap Implant Systems, LLC	2	$151
Axogen	1	$106
Si-bone, Inc.	1	$33
Avanos Medical	2	$31
Medtronic	1	$23
Johnson & Johnson	1	$18
Covidien LP	1	$16
Pacira Therapeutics, Inc.	1	$14
Amgen	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MAKO$104,269
OMNIBotics 3.0$75,490
NextAR Knee$14,610
GMK Sphere Revision System$8,372
Naviswiss Hip/Knee Systems$6,709
GMK SPHERE$4,144
AMISTEM$1,555
Naviswiss Hip navigation$1,547
Naviswiss Hip and Knee Navigation$1,500
AMIStem H Femoral Stems$1,239
GMK REVISION$752
Naviswiss Hip System$600
Corin Technology$600
TRIDENT$500
Corin Knees$323
Nalu Neurostimulation System$153
Naviswiss Hip/Knee Navigation$152
Sphere Knee, Efficiency, Hip Product Line$137
Naviswiss Knee Navigation$127
MYKNEE$122

How this compares

Too few adult reconstructive orthopaedic surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$634,039

Medicare patients

664

Services billed

2,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Celecoxib	413	$9,768
Tramadol Hcl	575	$2,632
Oxycodone Hcl	498	$2,348
Pregabalin	347	$1,946
Methocarbamol	366	$1,636
Meloxicam	106	$886
Cefadroxil	31	$294
Methylprednisolone	46	$274
Ondansetron OdtOndansetron	18	$200
Amoxicillin	158	$181
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	16	$129
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	16	$116
Gabapentin	11	$69
Clindamycin Hcl	33	$44

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Oklahoma City

Paul JacobOklahoma City$822K
Kyle McGivernOklahoma City$19K
Jacob HaynesOklahoma City$17K
Rishi ThakralOklahoma City$9K
John TompkinsOklahoma City$450
Scott DunitzTulsa$186K
Zackary BurrowTulsa$17K
James SlaterTulsa$7K
Ronald LabuttiTulsa$6K
Christian LuessenhopTulsa$4K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →